Clinical Trials Directory

Trials / Conditions / Metastatic Hormone-sensitive Prostate Cancer

Metastatic Hormone-sensitive Prostate Cancer

28 registered clinical trials studyying Metastatic Hormone-sensitive Prostate Cancer — 11 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingPhase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus
NCT07333066
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARDPhase 3
Active Not RecruitingA Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Ther
NCT07344779
Bayer—
RecruitingA Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
NCT07339267
Astellas Pharma Global Development, Inc.Phase 1
RecruitingA Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in Fra
NCT07451002
Janssen Cilag S.A.S.—
RecruitingA Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway
NCT07406282
Bayer—
RecruitingAn Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Me
NCT06991556
Novartis PharmaceuticalsPhase 2
RecruitingA Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154
Astellas Pharma Global Development, Inc.Phase 2
Not Yet RecruitingEvaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prost
NCT07031258
Nanfang Hospital, Southern Medical University—
Active Not RecruitingAn Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment
NCT06874114
Bayer—
RecruitingAn Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea
NCT06334120
Bayer—
CompletedAn Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgi
NCT06498921
Bayer—
CompletedNon-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer
NCT06452212
Astellas Pharma Korea, Inc.—
Not Yet RecruitingRezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer
NCT06134271
Jianbin BiPhase 2
Active Not RecruitingA Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen D
NCT05901649
Janssen-Cilag Ltd.—
RecruitingA Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
NCT05818683
Janssen Research & Development, LLCPhase 1
RecruitingPhase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb -
NCT05720130
AdvanCell Pty LimitedPhase 1 / Phase 2
Active Not RecruitingA Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in
NCT05059236
BayerPhase 2
CompletedSurvey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study
NCT05381311
Astellas Pharma Global Development, Inc.—
CompletedEfficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versu
NCT04934722
Merck Sharp & Dohme LLCPhase 3
CompletedPSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
NCT07428642
First Affiliated Hospital of Wenzhou Medical University—
Active Not RecruitingEfficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versu
NCT04191096
Merck Sharp & Dohme LLCPhase 3
Active Not RecruitingAn Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT i
NCT04076059
Astellas Pharma China, Inc.Phase 3
UnknownA Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
NCT03879122
Spanish Oncology Genito-Urinary GroupPhase 2 / Phase 3
CompletedNeoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive P
NCT03532217
Washington University School of MedicinePhase 1
WithdrawnToxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
NCT03343977
Peng Wang, MD PhDPhase 1 / Phase 2
CompletedDarolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitiv
NCT02799602
BayerPhase 3
CompletedA Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metas
NCT02677896
Astellas Pharma Global Development, Inc.Phase 3
CompletedAndrogen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
NCT00309985
ECOG-ACRIN Cancer Research GroupPhase 3